- Home
- CSBR vs CHRS Comparison
CSBR vs CHRS Comparison
Compare CSBR & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- CHRS
- Stock Information
- Founded
- CSBR 1985
- CHRS 2010
- Country
- CSBR United States
- CHRS United States
- Employees
- CSBR N/A
- CHRS N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSBR Health Care
- CHRS Health Care
- Exchange
- CSBR Nasdaq
- CHRS Nasdaq
- Market Cap
- CSBR 113.0M
- CHRS 112.5M
- IPO Year
- CSBR 1986
- CHRS 2014
- Fundamental
- Price
- CSBR $8.24
- CHRS $0.76
- Analyst Decision
- CSBR Strong Buy
- CHRS Buy
- Analyst Count
- CSBR 1
- CHRS 3
- Target Price
- CSBR $12.00
- CHRS $4.68
- AVG Volume (30 Days)
- CSBR 38.4K
- CHRS 1.2M
- Earning Date
- CSBR 07-17-2025
- CHRS 08-07-2025
- Dividend Yield
- CSBR N/A
- CHRS N/A
- EPS Growth
- CSBR N/A
- CHRS N/A
- EPS
- CSBR 0.46
- CHRS N/A
- Revenue
- CSBR $58,591,000.00
- CHRS $272,251,000.00
- Revenue This Year
- CSBR $15.11
- CHRS N/A
- Revenue Next Year
- CSBR $7.80
- CHRS $132.69
- P/E Ratio
- CSBR $17.82
- CHRS N/A
- Revenue Growth
- CSBR 19.03
- CHRS 19.87
- 52 Week Low
- CSBR $3.60
- CHRS $0.66
- 52 Week High
- CSBR $11.99
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- CSBR 69.99
- CHRS 40.60
- Support Level
- CSBR $6.27
- CHRS $0.74
- Resistance Level
- CSBR $8.58
- CHRS $0.79
- Average True Range (ATR)
- CSBR 0.64
- CHRS 0.05
- MACD
- CSBR 0.28
- CHRS 0.00
- Stochastic Oscillator
- CSBR 96.63
- CHRS 12.76
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.